Advanced Research in Age-Related Macular Degeneration: Special Issue

Oyuna Kozhevnikova
DOI: https://doi.org/10.3390/biomedicines12020392
IF: 4.757
2024-02-09
Biomedicines
Abstract:Age-related macular degeneration (AMD) is an eye disease that is the leading cause of irreversible vision loss in people over 55 years of age [...]
biochemistry & molecular biology,medicine, research & experimental,pharmacology & pharmacy
What problem does this paper attempt to address?
The paper primarily focuses on the research progress of Age-related Macular Degeneration (AMD), a major eye disease that leads to irreversible vision loss in people over 55 years old. With the global aging population, the number of AMD patients is expected to increase significantly in the coming decades. AMD is a complex disease influenced by various genetic and environmental factors, which determine the type, progression rate, and response to treatment. The paper explores molecular studies of AMD's pathological mechanisms and new methods for its early diagnosis, treatment, and prevention. Specifically, the paper covers the following aspects: 1. **Pathological Mechanisms of AMD**: Emphasizes the critical role of inflammation in the onset of AMD, particularly the importance of the complement system in dry AMD. 2. **New Therapies**: Introduces a drug called Pegcetacoplan (APL-2), a C3 inhibitor developed by Apellis Pharmaceuticals, which has been approved by the U.S. Food and Drug Administration for the treatment of dry AMD. 3. **Clinical Trial Evaluation**: Provides a methodological evaluation of the design, analysis, and interpretation of phase 3 clinical trials, discussing key attributes such as endpoint types, inclusion criteria, p-values, and effect sizes. 4. **Quantitative Autofluorescence (qAF8) Levels**: Finds that qAF8 levels decrease in the early progression of AMD, associated with the loss of function and integrity of retinal pigment epithelial cells. 5. **Protective Potential of JNK Inhibitors**: Evaluates the potential therapeutic effect of a JNK inhibitor, IQ-1S, for dry AMD. 6. **Relationship Between AMD and Diabetes**: Indicates that AMD patients do not have a higher risk of diabetes. 7. **Application of High-Resolution Imaging Technologies**: Optical Coherence Tomography (OCT) technology has improved the understanding of MNV types and distinguished different types of fundus lesions. 8. **Relationship Between Gene Polymorphisms and Treatment Response**: Studies the association between polymorphisms in autophagy-related genes and the response to anti-VEGF treatment. Overall, this paper aims to guide future AMD management strategies through new diagnostic methods, treatment options, and potential genetic and OCT markers.